日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

BRRIAR lncRNA alters breast cancer risk by modulating interferon signaling in cis and in trans

BRRIAR lncRNA 通过顺式和反式调节干扰素信号通路来改变乳腺癌风险。

Sivakumaran, Haran; Nair, Sneha; Bitar, Mainá; Lu, Xue; Wang, Lu; Liu, Ji; Karunarathne, Deshapriya S; Prakrithi, P; Jacquelin, Sebastien; Rivera, Isela Sarahi; Hillman, Kristine M; Kaufmann, Susanne; Ziegman, Rebekah; Shi, Wei; Alexandrou, Sarah; Caldon, C Elizabeth; Veedu, Rakesh N; Nguyen, Quan H; Beesley, Jonathan; Wykes, Michelle N; French, Juliet D; Edwards, Stacey L

JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer.

JNK通路抑制介导ER+乳腺癌对联合内分泌治疗和CDK4/6抑制剂的不敏感性

Alexandrou Sarah, Lee Christine S, Fernandez Kristine J, Wiharja Celine E, Eshraghi Leila, Reeves John, Reed Daniel A, Portman Neil, Phan Zoe, Milioli Heloisa H, Nikolic Iva, Cadell Antonia L, Croucher David R, Simpson Kaylene J, Lim Elgene, Hickey Theresa E, Millar Ewan K A, Alves Carla L, Ditzel Henrik J, Caldon C Elizabeth

Unmatched Cell Line Collections Are Not Optimal for Identification of PARP Inhibitor Response and Drug Synergies

不匹配的细胞系集合并非鉴定PARP抑制剂反应和药物协同作用的最佳选择

Phan, Zoe; Fernandez, Kristine J; Caldon, C Elizabeth

SAM-DNMT3A, a strategy for induction of genome-wide DNA methylation, identifies DNA methylation as a vulnerability in ER-positive breast cancers.

SAM-DNMT3A 是一种诱导全基因组 DNA 甲基化的策略,它发现 DNA 甲基化是 ER 阳性乳腺癌的一个弱点

Hosseinpour Mahnaz, Xi Xinqi, Liu Ling, Malaver-Ortega Luis, Perlaza-Jimenez Laura, Joo Jihoon E, York Harrison M, Beesley Jonathan, Caldon C Elizabeth, Dugué Pierre-Antoine, Dowty James G, Arumugam Senthil, Southey Melissa C, Rosenbluh Joseph

miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma

miR-99b-5p、miR-380-3p 和 miR-485-3p 是高危神经母细胞瘤中新型的化疗增敏 miRNA。

Holliday, Holly; Yang, Jessica; Dodson, Eoin; Nikolic, Iva; Kamili, Alvin; Wheatley, Madeleine; Deng, Niantao; Alexandrou, Sarah; Davis, Thomas P; Kavallaris, Maria; Caldon, C Elizabeth; McCarroll, Joshua; De Preter, Katleen; Mestdagh, Pieter; Marshall, Glenn M; Simpson, Kaylene J; Fletcher, Jamie; Swarbrick, Alexander

The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer

表观遗传疗法靶向内分泌耐药性乳腺癌三维表观基因组的潜力

Achinger-Kawecka, Joanna; Stirzaker, Clare; Portman, Neil; Campbell, Elyssa; Chia, Kee-Ming; Du, Qian; Laven-Law, Geraldine; Nair, Shalima S; Yong, Aliza; Wilkinson, Ashleigh; Clifton, Samuel; Milioli, Heloisa H; Alexandrou, Sarah; Caldon, C Elizabeth; Song, Jenny; Khoury, Amanda; Meyer, Braydon; Chen, Wenhan; Pidsley, Ruth; Qu, Wenjia; Gee, Julia M W; Schmitt, Anthony; Wong, Emily S; Hickey, Theresa E; Lim, Elgene; Clark, Susan J

CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective

2023 年对雌激素受体阳性乳腺癌 CDK4/6 抑制剂耐药性的展望

Zhou, Fiona H; Downton, Teesha; Freelander, Allegra; Hurwitz, Joshua; Caldon, C Elizabeth; Lim, Elgene

High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer

细胞周期蛋白E1蛋白水平高(而非基因扩增)是基底样乳腺癌的预后指标。

Aziz, Diar; Lee, Christine; Chin, Venessa; Fernandez, Kristine J; Phan, Zoe; Waring, Paul; Caldon, C Elizabeth

Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer

雌激素受体结合位点的表观遗传重编程改变了内分泌耐药性乳腺癌的三维染色质结构

Achinger-Kawecka, Joanna; Valdes-Mora, Fatima; Luu, Phuc-Loi; Giles, Katherine A; Caldon, C Elizabeth; Qu, Wenjia; Nair, Shalima; Soto, Sebastian; Locke, Warwick J; Yeo-Teh, Nicole S; Gould, Cathryn M; Du, Qian; Smith, Grady C; Ramos, Irene R; Fernandez, Kristine F; Hoon, Dave S; Gee, Julia M W; Stirzaker, Clare; Clark, Susan J

Editorial: Proceedings From ACCM19: Cell Cycle, DNA Damage Response and Telomeres

社论:ACCM19会议论文集:细胞周期、DNA损伤反应和端粒

Burgess, Andrew; Caldon, C Elizabeth